Life Sciences
Finance and operating leadership for life sciences
Life sciences companies run on capital and milestones. You raise to reach the next data readout, the next regulatory step, the next commercial inflection, and the finance function has to hold up to scrutiny from sophisticated investors the whole way. The science is hard enough. The operating discipline behind it shouldn’t be the thing that slows you down or scares off a fund.
We bring fractional and interim executives who have run finance and operations in regulated, capital-intensive businesses. Diagnostics, medical devices, biotech, healthcare IT. Our leaders have built the model that determines how much you need to raise to hit each milestone, taken companies through institutional rounds, and stood up the controls that public markets and acquirers require.
What we do for life sciences companies
Capital strategy and fundraising. We build the financial model that ties your raise to your milestones, develop the investor presentation, identify and reach the right funds, and run the process through close. For companies that need to know exactly how much capital gets them to the next value point, this is the work. [Link: Capital Raise & Finance Operations]
Finance operations that investors trust. Clean books, GAAP-compliant policies, and audit-ready reporting from the start, scaled to your stage. Investors in this sector check the numbers hard. We make sure they hold up. [Link: Fractional & Interim CFO]
Public-company and exit readiness. SEC reporting, controls, and the institutional rigor that an IPO or an acquisition demands. We’ve guided newly public companies through high-stakes reporting cycles in cash-constrained environments.
Operating discipline through scale. Cash preservation, run-rate management, and the operating model to make limited capital go further, which in this sector is often the difference between reaching the next milestone and not.
Why life sciences companies choose Everest
This is a sector where general advice doesn’t help. You need people who understand milestone-based financing, regulatory timelines, and the way investors in diagnostics or devices or biotech actually evaluate a company. Our Managing Directors have sat in those seats. We pair that experience with AI that reads the business the way an investor would, and a deep bench across finance, operations, and HR, so you can add capability as the company grows without restarting each time.
Proof
A diagnostics company preparing to raise its Series A engaged us to lead the round as CFO. We rebuilt the financial model to determine the proceeds required to hit key milestones, developed a venture-ready investor presentation, identified target investors, and introduced the company to more than 150 funds and 15 merchant and investment banks.
A telehealth company working to reduce unnecessary hospital transfers from skilled nursing facilities was struggling to raise its Series B. We revised the investor materials and model, led a targeted outreach process, and prepared management for diligence. The company secured a $24M Series B led by a top healthcare investor.
Frequently asked questions
Do you work with pre-revenue biotech? Yes. Much of our life sciences work is with pre-revenue and milestone-stage companies where the central question is how much capital gets you to the next value inflection.
Can you help us get ready for an IPO? Yes. We establish the reporting, controls, and finance infrastructure public markets require, and we’ve supported companies through public reporting cycles directly.
Which life sciences subsectors do you cover? Diagnostics, medical devices, biotech, and healthcare IT, among others. Our leaders have operated across the regulated, capital-intensive parts of the sector.
Let's talk
If you’re raising, scaling, or preparing for a transaction in life sciences, let’s talk. We’ve sat in your seat. Now we’re in your corner.
